The global bioresorbable coronary stents market size 2026 represents an innovative segment within the cardiovascular medical devices industry. These stents, also known as bioresorbable scaffolds or biodegradable stents, are designed to open blocked heart arteries and are eventually absorbed by the body over time, unlike traditional metal stents that remain permanently. Made from polymers or degradable metals, these devices aim to restore natural vessel function while reducing long-term complications associated with permanent metallic implants.
According to Fortune Business Insights, the market was valued at USD 356.03 million in 2025 and is projected to grow from USD 372.81 million in 2026 to USD 593.15 million by 2034, exhibiting a compound annual growth rate of 5.98% during the forecast period. North America currently leads the global market with substantial market share.
Key Market Drivers
The primary catalyst for market expansion is the escalating prevalence of cardiovascular diseases worldwide. In October 2024, the Centers for Disease Control and Prevention reported that nearly 1 in 20 U.S. adults aged 20 and older suffered from coronary artery disease in 2023. The rising incidence of CAD is attributed to various lifestyle factors including excessive alcohol consumption, smoking, sedentary behavior, and increasing stress levels. Additionally, the aging global population presents a higher risk for coronary artery disease, further amplifying demand for interventional treatments.
Bioresorbable coronary stents offer several clinical advantages that drive their adoption. They enable restored vasomotion, eliminate long-term metallic presence in vessels, and potentially reduce the risk of late stent thrombosis. These benefits position them as an attractive alternative to permanent metallic stents for appropriate clinical scenarios.
Get a Free Sample PDF Of This Report - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bioresorbable-coronary-stents-market-113733
Market Restraints and Challenges
Despite promising potential, the market faces significant headwinds. Established alternatives such as drug-eluting and bare metal stents present formidable competition due to their proven track record, demonstrated durability, and lower cost profile. These traditional options remain preferred in numerous clinical cases, potentially limiting bioresorbable stent adoption.
Long-term safety and efficacy data for bioresorbable coronary stents are still under investigation. While early clinical trials have shown encouraging results, more extensive and robust clinical evidence is needed to fully establish long-term benefits and address potential complications such as restenosis. This knowledge gap may hinder broader market acceptance among clinicians.
The high costs associated with bioresorbable coronary stents pose another significant barrier, with average treatment costs ranging from USD 2,500 to USD 5,000 in India as of June 2025. Advanced biomaterials and manufacturing processes contribute to elevated production expenses, which translate to higher prices for healthcare providers and patients. This cost factor particularly limits adoption in price-sensitive regions and countries with limited reimbursement frameworks.
Market Opportunities
Expanding healthcare infrastructure and increasing awareness about heart diseases in developing regions present substantial growth opportunities. In September 2023, the Indian Ministry of Health launched a public campaign on heart health during World Heart Day, exemplifying efforts to raise disease awareness. Multispecialty hospitals are increasingly focusing on expanding cardiology services to meet growing demand for coronary artery interventions, which could drive bioresorbable stent utilization.
Market Segmentation Insights
By Material: The market divides into metal-based and polymer-based stents. Metal-based stents dominated in 2024, benefiting from technological advancements that enhance treatment outcomes. According to data published in the Journal of Magnesium and Alloy in March 2025, advancements in surface engineering and alloying of magnesium-based stents have potentially addressed limitations of traditional stents, including in-stent restenosis and long-term complications. Polymer-based stents are expected to grow significantly, driven by their potential to overcome prolonged anticoagulation requirements associated with metallic options.
By Application: The chronic coronary syndrome segment held the dominant position in 2024, reflecting the substantial burden of coronary artery disease. Data reported by the Journal of the American College of Cardiology in April 2024 stated that around 315.0 million coronary artery disease cases occurred globally in 2022. The acute coronary syndrome segment also maintains a substantial share, supported by increasing percutaneous coronary intervention procedures.
By End-User: Hospitals and ambulatory surgical centers dominated the market in 2024, driven by the growing number of angioplasty procedures performed in these settings. Strategic initiatives such as Bon Secours Mercy Health, Compass Surgical Partners, and AlignedCardio's plan to open a cardiovascular ASC in late 2025 in the Short Pump area of Henrico, Virginia support procedural volume growth. Specialty clinics represent the second-largest segment, benefiting from the proliferation of cardiology clinics globally.
Regional Market Analysis
North America leads the global market, valued at USD 138.50 million in 2025. The region benefits from well-established healthcare infrastructure supporting significant coronary intervention volumes. According to the Journal of the American College of Cardiology in December 2024, more than 18.0 million U.S. individuals have CAD, driving demand for advanced cardiovascular treatments.
Europe holds the second-largest market share, with growth driven by company focus on product introductions and increasing obesity rates. As of May 2024, 25.6% of adults were estimated to be living with obesity between 2021 and 2022 in England, contributing to CAD prevalence.
Asia Pacific ranks third globally, with market growth fueled by increasing smoking rates and lifestyle factors posing cardiovascular risks. According to a study published by the NCBI in November 2023, the proportion of cases receiving stent treatment increased from 13.8% in 2019 to 19.4% in 2021 in the region.
Competitive Landscape
Boston Scientific Corporation, Terumo Corporation, and MicroPort Scientific Corporation dominate the global market, focusing on new product introductions to maintain their leadership positions. Other key players including Lepu Medical, Elixir Medical, Relisys Medical Devices Limited, SINOMED, Reva Medical LLC, and ELLA-CS are pursuing geographic expansion through partnerships, facility launches, and commercialization in untapped markets.
Recent Industry Developments
In April 2025, MicroPort Scientific Corporation and its 16 affiliates presented over 80 advanced innovations at the 91st China International Medical Equipment Fair, including bioresorbable coronary stents. Earlier, in July 2024, MicroPort's subsidiary Shanghai MicroPort Medical Group received approval from China's National Medical Products Administration for Firesorb, a fully bioresorbable cardiac stent.
Biotronik announced CE approval and market introduction of Freesolve resorbable magnesium scaffold in the European market in February 2024. These regulatory approvals and product launches demonstrate ongoing innovation and market expansion efforts by leading manufacturers.
Market Trends and Future Outlook
Ongoing research and development efforts focus on improving bioresorbable coronary stent performance, safety, and efficacy through new materials, optimized designs, and enhanced drug-elution capabilities. In May 2024, BIOTRONIK enrolled the first patient in the BIOMAG-II trial to evaluate the safety and clinical performance of its Freesolve, a new-generation resorbable magnesium scaffold.
Emerging trends include the integration of biosensors for real-time patient monitoring and personalized treatment approaches, which could enable more timely interventions and improved patient outcomes. Hybrid designs combining bioresorbable and permanent stent components may offer balanced benefits, potentially addressing limitations of fully bioresorbable options while optimizing long-term results.
The market's future trajectory appears positive, supported by increasing cardiovascular disease burden, technological advancements, expanding healthcare infrastructure in developing regions, and growing clinical evidence. However, success will depend on addressing current challenges including cost barriers, generating robust long-term safety data, and demonstrating clear clinical advantages over established alternatives.